Molecular status of plasma fibronectin as an additional biomarker for assessment of alzheimer's dementia risk

Dementia and Geriatric Cognitive Disorders

Volumn 28, Issue 4, 2009, Pages 338-342

  Lemańska Perek, Anna ^a   Leszek, Jerzy ^a   Krzyanowska Gola̧b, Dorota ^a   Radzik, Jacek ^a   Ka̧tnik Prastowska, M Iwona ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Alzheimer's disease; Biomarker; Fibronectin; High molecular weight fibronectin

Indexed keywords

FIBRONECTIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; FEMALE; HUMAN; IMMUNOBLOTTING; MALE; MOLECULAR WEIGHT; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DENSITOMETRY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FIBRONECTINS; HUMANS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; RISK ASSESSMENT;

EID: 70350426110     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000252764     Document Type: Article

References (22)

1. Zlokovic BV: New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 2008; 5: 409-414.
2. Bell RD, Zlokovic BV: Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009; 118: 103-113.
3. Desai BS, Schneider JA, Li JL, Carvey PM, Hendey B: Evidence of angiogenic vessels in Alzheimer's disease. J Neural Transm 2009; 116: 587-597.
4. Caltagarone J, Jing Z, Bowser R: Focal adhesions regulate A β signaling and cell death in Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis 2007; 1772: 438-445.
5. Mao Y, Schwarzbauer JE: Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol 2005; 24: 389-399.
6. Magnusson MK, Mosher DF: Fibronectin: structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol 1998; 18: 1363-1370.
7. Geiger B, Bershadsky A, Pankov R, Yamada KM: Transmembrane extracellular matrixcytoskeleton crosstalk. Mol Cell Biol 2001; 2: 793-805.
8. Martin H, Lambert MP, Barber K, Hinton S, Klein WL: Alzheimer's associated phosphotau epitope in human neuroblastoma cell cultures: up-regulation by fibronectin and laminin. Neuroscience 1995; 66: 769-779.
9. Stupack DG, Cheresh D: Apoptotic cues from the extracellular matrix regulators of angiogenesis. Oncogene 2003; 22: 9022-9029.
10. Wijelath ES, Rahman S, Namekata M, Murray J, Nishimura T, Mostafavi-Pour Z, Patel Y, Suda Y, Humphries Mj, Sobel M: Heparin- II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 2006; 13: 853-860.
11. Wang I, Milner R: Fibronectin promotes brain capillary endothelial cell survival and proliferation through α 5 β 1 and α v β 3 integrins via MAP kinase signalling. J Neurochem 2006; 96: 148-159.
12. Milner R: A novel three-dimensional system to study interactions between endothelial cells and neural cells of the developing central nervous system. BMC Neurosci 2007; 8: 3.
13. Ray S, Britschgi M, Herbert Ch, Takeda- Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici DG, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss- Coray T: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine 2007; 13: 1359-1362.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS - ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
15. Hirnle L, Ka̧tnik-Prastowska I: Amniotic fibronectin fragmentation and domain and sialyl- and fucosyl-glycotope expression associated with pregnancy complicated by intrauterine infection. Clin Chem Lab Med 2007; 45: 208-214.
16. Pupek M, Krzyanowska-Goła̧b D, Dyła T, Lemañska-Perek A, Jankowska R, Ka̧tnik- Prastowska I: Presence of high-molecularweight forms and domain alterations of fibronectin in pleural effusion of patients with lung cancer. Clin Biochem 2009; 42: 654-661.
17. Toyoshima K, Kimura S, Cheng J, Oda Y, Mori KJ, Saku T: High-molecular-weight fibronectin synthesized by adenoid cystic carcinoma cells of salivary gland origin. Jpn J Cancer Res 1999; 90: 308-319.
18. Schaal-Jensen R, Kiehr B, Boesen HT, Krabbe JS, Sommer C, Jacobsen H, Oleksiewicz MB: Characterization of high molecular weight plasma protein complexes induced by clotting factor rFXIII-treatment in the cynomolgus monkey. J Thromb Haemost 2007; 5: 2070-2078.
19. Makogonenko E, Ingham KC, Medved L: Interaction of the fibronectin COOH-terminal Fib-2 regions with fibrin: further characterization and localization of the Fib-2 binding sites. Biochemistry 2007; 8: 5418-5426.
20. Yi M, Sakai T, Fassler R, Ruoslahti E: Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci USA 2003; 100: 11435-11438.
21. Majors AK, Sengupta S, Willard B, Kinter MT, Pyeritz RE, Jacobsen DW: Homocysteine binds to human plasma fibronectin and inhibits its interaction with fibrin. Arterioscler Thromb Vasc Biol 2002; 22: 1354-1359.
22. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, Lucca U: Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 2004; 80: 114-122.